Researchers at the National Institute of Neurological Disorders and Stroke (NINDS) are seeking patients with HTLV-1-associated myelopathy or tropical spastic paraparesis (HAM/TSP) for an experimental treatment trial. The study will test an experimental drug's ability to ameliorate the immune dysregulation induced by HTLV-1. Testing of this drug will be carried out in compliance with FDA guidelines.
Eligible patients must be at least 16 years of age, meet diagnostic criteria for HAM/TSP, and be negative for HIV, HCV, and hepatitis B surface antigen. The studies will be conducted at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD. All study-related expenses will be paid by the NIH.
For more information, physicians should send a referral letter and a copy of the patient's recent medical records to Joan Eaton, RN, CRNP, Neuroimmunology Branch, NINDS, NIH, Building 10, Room 5B16, 10 Center Drive MSC 1430, Bethesda, MD 20892-1430; telephone: (301) 496-0064; fax: (301) 402-0373; email: email@example.com.